Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
INFNALAMEDA, Calif.--(BUSINESS WIRE)-- #antibodies--Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
INFNALAMEDA, Calif.--(BUSINESS WIRE)-- #antibodies--Infinimmune Launches GLIMPSE-1 AI Model Trained Exclusively on Human Antibody Sequences for Advanced Therapeutic Engineering
Infinera Q4 2024 Adj EPS $0.03 Misses $0.11 Estimate, Sales $414.40M Beat $409.07M Estimate
INFNInfinera Announced That Its Pending Acquisition By Nokia Corporation Is Anticipated To Be Completed On Or About February 28, 2025
INFNNokia Set To Gain Unconditional EU Antitrust Approval For Its $2.3B Acquisition Of Infinera, Sources Say
INFNRosenblatt Maintains Neutral on Infinera, Maintains $6.65 Price Target
INFNInfinera Q3 Sales $354.40M Miss $402.87M Estimate
INFNInfinera Received Nasdaq Delinquency Notification
INFNNeedham Reiterates Buy on Infinera, Maintains $10 Price Target
INFNExpert Ratings for Infinera
INFNAnalysts have provided the following ratings for Infinera (NASDAQ:INFN) within the last quarter:
Morgan Stanley Maintains Equal-Weight on Infinera, Lowers Price Target to $7.5
INFNB. Riley Securities Maintains Buy on Infinera, Lowers Price Target to $11
INFNCitigroup Maintains Neutral on Infinera, Lowers Price Target to $9
INFNInfinera: Q1 Earnings Insights
INFNInfinera (NASDAQ:INFN) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
Earnings
Infinera missed estimated earnings by 75.0%, reporting an EPS of $-0.07 versus an estimate of $-0.04.
Infinera Sees Q2 Sales $330M-$370M vs $379.93M Est.
INFNInfinera Q1 Adj. EPS $(0.07) Misses $(0.04) Estimate, Sales $338.90M Miss $361.74M Estimate
INFN